5 Stocks Driving The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 65 points (-0.4%) at 16,380 as of Friday, Jan. 10, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,832 issues advancing vs. 1,123 declining with 123 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is down 0.2%. Top gainers within the sector include Intercept Pharmaceuticals ( ICPT), up 58.9%, Boston Scientific ( BSX), up 1.6%, AstraZeneca ( AZN), up 1.2% and Bristol-Myers Squibb Company ( BMY), up 0.9%. On the negative front, top decliners within the sector include Biomarin Pharmaceutical ( BMRN), down 2.1%, Celgene Corporation ( CELG), down 2.1%, Amgen ( AMGN), down 2.0%, UnitedHealth Group ( UNH), down 1.8% and Humana ( HUM), down 1.6%.

TheStreet would like to highlight 5 stocks pushing the sector higher today:

5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $0.56 (1.5%) to $38.85 on average volume. Thus far, 905,220 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $38.40-$38.91 after having opened the day at $38.47 as compared to the previous trading day's close of $38.29.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $20.0 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Incyte ( INCY) is up $1.68 (3.0%) to $57.85 on heavy volume. Thus far, 2.6 million shares of Incyte exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $57.29-$59.15 after having opened the day at $57.29 as compared to the previous trading day's close of $56.17.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $8.8 billion and is part of the drugs industry. Shares are up 10.9% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk. Get the full Incyte Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Intuitive Surgical ( ISRG) is up $11.74 (3.0%) to $398.52 on heavy volume. Thus far, 389,888 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 448,100 shares. The stock has ranged in price between $385.27-$399.06 after having opened the day at $386.47 as compared to the previous trading day's close of $386.78.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $14.5 billion and is part of the health services industry. The company has a P/E ratio of 22.8, above the S&P 500 P/E ratio of 17.7. Shares are up 0.7% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Intuitive Surgical a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full Intuitive Surgical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Actavis ( ACT) is up $1.68 (0.9%) to $181.62 on average volume. Thus far, 709,552 shares of Actavis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $180.81-$186.74 after having opened the day at $186.47 as compared to the previous trading day's close of $179.94.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $30.8 billion and is part of the drugs industry. Shares are up 7.1% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate Actavis a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Medtronic ( MDT) is up $0.56 (0.9%) to $59.92 on average volume. Thus far, 2.0 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $59.29-$60.16 after having opened the day at $59.67 as compared to the previous trading day's close of $59.36.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. Medtronic has a market cap of $60.7 billion and is part of the health services industry. The company has a P/E ratio of 16.3, below the S&P 500 P/E ratio of 17.7. Shares are up 3.4% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Medtronic a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Medtronic Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade